$996 Million is the total value of Vivo Capital, LLC's 49 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 13.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRMY | Sell | Harmony Biosciences Holdings Inc | $199,654,000 | -10.2% | 4,093,785 | -10.4% | 20.05% | +30.9% |
| SRRA | Sell | Sierra Oncology, Inc | $183,090,000 | +71.6% | 3,329,509 | -0.0% | 18.38% | +150.2% |
| TIL | Instil Bio Inc | $57,689,000 | -57.0% | 12,486,787 | 0.0% | 5.79% | -37.3% | |
| ISEE | Sell | Iveric Bio Inc | $50,396,000 | -53.4% | 5,238,634 | -18.6% | 5.06% | -32.1% |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | 0.0% | 5,900,000 | 0.0% | 3.83% | +45.8% | |
| ALXO | ALX Oncology Holdings Inc | $34,140,000 | -52.1% | 4,220,048 | 0.0% | 3.43% | -30.2% | |
| TARS | Sell | Tarsus Pharmaceuticals Inc | $33,761,000 | -32.8% | 2,312,368 | -22.6% | 3.39% | -2.0% |
| IMPL | Impel NeuroPharma Inc | $26,886,000 | +46.3% | 2,884,789 | 0.0% | 2.70% | +113.4% | |
| GERN | Geron Corp | $23,619,000 | +14.0% | 15,238,095 | 0.0% | 2.37% | +66.2% | |
| Ventyx Biosciences Inc | $23,503,000 | -9.9% | 1,921,726 | 0.0% | 2.36% | +31.4% | ||
| AMRS | Amyris, Inc | $21,538,000 | -57.6% | 11,642,195 | 0.0% | 2.16% | -38.1% | |
| COGT | Cogent Biosciences Inc | $17,327,000 | +20.4% | 1,920,941 | 0.0% | 1.74% | +75.6% | |
| KDNY | Chinook Therapeutics Inc | $15,254,000 | +6.9% | 872,151 | 0.0% | 1.53% | +55.8% | |
| KALV | KalVista Pharmaceuticals Inc. | $15,090,000 | -33.2% | 1,533,559 | 0.0% | 1.52% | -2.7% | |
| CLDX | Sell | Celldex Therapeutics Inc | $15,061,000 | -29.6% | 558,636 | -11.1% | 1.51% | +2.6% |
| VRDN | Viridian Therapeutics Inc | $15,041,000 | -37.4% | 1,300,000 | 0.0% | 1.51% | -8.8% | |
| IO Biotech Inc | $14,083,000 | -11.9% | 3,015,545 | 0.0% | 1.41% | +28.4% | ||
| GTH | Buy | Genetron Holdings Ltdads | $13,811,000 | -14.9% | 8,124,174 | +9.6% | 1.39% | +24.1% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $13,574,000 | -73.9% | 146,025 | -67.0% | 1.36% | -61.9% |
| LEGN | Legend Biotech Corp Sponsoredsponsored ads | $13,441,000 | +51.3% | 244,375 | 0.0% | 1.35% | +120.6% | |
| RLMD | Relmada Therapeutics Inc | $13,405,000 | -29.6% | 705,882 | 0.0% | 1.35% | +2.6% | |
| ACRS | Aclaris Therapeutics, Inc. | $12,545,000 | -19.0% | 898,631 | 0.0% | 1.26% | +18.1% | |
| VRNA | Verona Pharma PLCads | $11,522,000 | -16.0% | 2,749,918 | 0.0% | 1.16% | +22.4% | |
| MRUS | Merus NV | $10,007,000 | -14.4% | 442,000 | 0.0% | 1.00% | +24.8% | |
| ZLAB | Buy | Zai Lab Ltd ADRadr | $9,417,000 | +17.9% | 271,528 | +49.5% | 0.95% | +72.0% |
| BLU | Bellus Health Inc | $9,398,000 | +34.3% | 1,017,152 | 0.0% | 0.94% | +95.9% | |
| VERA | Vera Therapeutics Inc | $9,073,000 | -42.1% | 666,666 | 0.0% | 0.91% | -15.5% | |
| BOLT | Bolt Therapeutics Inc | $7,897,000 | -25.5% | 3,871,291 | 0.0% | 0.79% | +8.6% | |
| IOVA | Iovance Biotherapeutics Inc | $7,232,000 | -33.7% | 655,057 | 0.0% | 0.73% | -3.3% | |
| AVDL | Avadel Pharmaceuticals PLCadr | $7,167,000 | -64.3% | 2,937,093 | 0.0% | 0.72% | -47.9% | |
| OLMA | Olema Pharmaceuticals Inc | $6,876,000 | -4.5% | 1,689,515 | 0.0% | 0.69% | +39.1% | |
| DSGN | Design Therapeutics | $6,672,000 | -13.3% | 476,589 | 0.0% | 0.67% | +26.4% | |
| TERN | Terns Pharmaceuticals Inc | $6,634,000 | -16.5% | 2,675,133 | 0.0% | 0.67% | +21.8% | |
| Sell | Aadi Bioscience Inc | $6,278,000 | -52.1% | 509,572 | -34.0% | 0.63% | -30.2% | |
| CMPX | Compass Therapeutics Inc | $5,300,000 | +93.4% | 2,000,000 | 0.0% | 0.53% | +181.5% | |
| GRCL | Gracell Biotechnologies Incsponsored ads | $5,287,000 | +136.0% | 961,359 | 0.0% | 0.53% | +244.8% | |
| Minerva Surgical Inc | $5,207,000 | -47.8% | 2,215,667 | 0.0% | 0.52% | -23.9% | ||
| STSA | Satsuma Pharmaceuticals Inc | $5,102,000 | +8.9% | 1,232,394 | 0.0% | 0.51% | +59.0% | |
| ARWR | Arrowhead Pharmaceuticals Inc | $4,838,000 | -23.4% | 137,411 | 0.0% | 0.49% | +11.7% | |
| ALGS | Aligos Therapeutics Inc | $4,292,000 | -43.7% | 3,547,030 | 0.0% | 0.43% | -17.9% | |
| CDXS | Codexis, Inc | $4,060,000 | -49.3% | 388,144 | 0.0% | 0.41% | -26.0% | |
| DYN | Dyne Therapeutics Inc | $3,968,000 | -28.7% | 577,642 | 0.0% | 0.40% | +3.9% | |
| Sera Prognostics Inc | $3,044,000 | -56.7% | 1,856,011 | 0.0% | 0.31% | -36.8% | ||
| RZLT | New | Rezolute Inc | $1,581,000 | – | 489,473 | +100.0% | 0.16% | – |
| ZYME | Zymeworks Inc | $1,516,000 | -19.1% | 286,064 | 0.0% | 0.15% | +17.8% | |
| ASLN | Aslan Pharmaceuticals Ltdads | $1,406,000 | -45.0% | 2,840,909 | 0.0% | 0.14% | -19.9% | |
| FIXX | Sell | Homology Medicines, Inc. | $729,000 | -71.9% | 370,068 | -56.6% | 0.07% | -59.2% |
| DTIL | Precision Biosciences Inc | $224,000 | -48.1% | 140,255 | 0.0% | 0.02% | -26.7% | |
| MTCR | Metacrine Inc | $73,000 | -18.0% | 146,426 | 0.0% | 0.01% | +16.7% | |
| EIGR | Exit | Eiger BioPharmaceuticals Inc | $0 | – | -4,166 | -100.0% | -0.00% | – |
| ELEV | Exit | Elevation Oncology Inc | $0 | – | -496,844 | -100.0% | -0.09% | – |
| Exit | Dice Therapeutics Inc | $0 | – | -163,136 | -100.0% | -0.22% | – | |
| MREO | Exit | Mereo Biopharma Group PLCads | $0 | – | -3,795,225 | -100.0% | -0.29% | – |
| NKTX | Exit | Nkarta Inc | $0 | – | -512,225 | -100.0% | -0.40% | – |
| NFH | Exit | New Frontier Health Corp | $0 | – | -14,300,000 | -100.0% | -11.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.